Luc Marengère
Direttore/Membro del Consiglio presso Ixchelsis Ltd.
Profilo
Luc Marengère is currently a Director at Emovi, Inc., Ixchelsis Ltd., Modulate Therapeutics, Inc., AurKa Pharma, Inc., Access Vascular, Inc., and Panthera Dental Inc. He is also the Managing Partner at TVM Life Science Management, Inc. since 2012.
In the past, he served as a Director at Cita NeuroPharmaceuticals, Inc., Cytochroma, Inc., Rapid Micro Biosystems, Inc., Acer Therapeutics, Inc., Argos Therapeutics, Inc., Aegera Therapeutics, Inc., Trillium Therapeutics, Inc., LymphoSign, Inc., VisualSonics, Inc., and Opexa Therapeutics, Inc. He was also an Independent Director at CoLucid Pharmaceuticals, Inc. from 2015 to 2017 and at Acer Therapeutics, Inc. from 2017 to 2019.
Additionally, he worked as a Researcher at Amgen, Inc., Investment Manager at Lumira Capital Investment Management, Inc., Managing General Partner at VenGrowth Capital Partners, Inc., Co-President & Partner at CDP Capital Private Equity, Analyst at MedTech Partners, Inc., and Principal at University Medical Discoveries, Inc. Dr. Marengère holds a graduate degree from Queen's University, an undergraduate degree from the University of Ottawa, and a doctorate degree from the University of Toronto.
Posizioni attive di Luc Marengère
Società | Posizione | Inizio |
---|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Direttore/Membro del Consiglio | - |
TVM Life Science Management, Inc. | Corporate Officer/Principal | 01/03/2012 |
Modulate Therapeutics, Inc.
Modulate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada. | Direttore/Membro del Consiglio | - |
AurKa Pharma, Inc.
AurKa Pharma, Inc. BiotechnologyHealth Technology AurKa Pharma, Inc. develops medication for cancer treatment. The company was founded by Caroline Fortier and is headquartered in Montreal, Canada. | Direttore/Membro del Consiglio | - |
Panthera Dental Inc.
Panthera Dental Inc. Medical SpecialtiesHealth Technology Panthera Dental Inc. engages in prosthetic implant solutions and dental sleep appliances. Its products include metal implant bar, integrated bar, diamart, ReBourke, Copywax, Angulated Screw Channel, and Components and Attachment. The company was founded by Bernard Robichaud, Gabriel Robichaud, and Beatrice Robichaud in 2011 and is headquartered in Quebec, Canada. | Direttore/Membro del Consiglio | - |
Emovi, Inc.
Emovi, Inc. Medical/Nursing ServicesHealth Services Emovi, Inc. offers orthopedic services. It offers services to people suffering from knee osteoarthritis, ligament or meniscus tears, patello-femoral syndrome, tendonitis, and biomechanical deficiencies causing pain and disability. The company was founded in 2002 and is headquartered in Montr?al, Canada. | Direttore/Membro del Consiglio | - |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Luc Marengère
Società | Posizione | Fine |
---|---|---|
ACER THERAPEUTICS INC. | Direttore/Membro del Consiglio | 17/05/2019 |
COLUCID PHARMACEUTICALS INC | Direttore/Membro del Consiglio | 01/03/2017 |
░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
Formazione di Luc Marengère
Queen's University | Graduate Degree |
University of Ottawa | Undergraduate Degree |
University of Toronto | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
AMGEN INC. | Health Technology |
RAPID MICRO BIOSYSTEMS, INC. | Producer Manufacturing |
Aziende private | 26 |
---|---|
Cita NeuroPharmaceuticals, Inc.
Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Health Technology |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | Health Technology |
CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
Acer Therapeutics, Inc. /Old/
Acer Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. develops therapeutics for the treatment of orphan diseases. Its current pipeline consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD). The company was founded by Chris Schelling and is headquartered in Cambridge, MA. | Health Technology |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
VenGrowth Capital Partners, Inc.
VenGrowth Capital Partners, Inc. Investment ManagersFinance Founded in 1982, VenGrowth Capital Partners, Inc. is a private equity and venture capital firm located in Toronto, Ontario. The firm is a subsidiary of Covington Capital Corp. They manage retail and institutional assets. | Finance |
Argos Therapeutics, Inc.
Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
CDP Capital Private Equity
CDP Capital Private Equity Investment ManagersFinance CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London. | Finance |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
MedTech Partners, Inc.
MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Finance |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
VisualSonics, Inc.
VisualSonics, Inc. Medical SpecialtiesHealth Technology VisualSonics, Inc. developed vivo imaging systems for non-invasive small animal research. The company was founded by F. Stuart Foster in 1999 and headquartered in Toronto, Canada. | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
University Medical Discoveries, Inc.
University Medical Discoveries, Inc. Investment ManagersFinance University Medical Discoveries, Inc. (UMDI) is a venture capital firm located in Toronto. | Finance |
Emovi, Inc.
Emovi, Inc. Medical/Nursing ServicesHealth Services Emovi, Inc. offers orthopedic services. It offers services to people suffering from knee osteoarthritis, ligament or meniscus tears, patello-femoral syndrome, tendonitis, and biomechanical deficiencies causing pain and disability. The company was founded in 2002 and is headquartered in Montr?al, Canada. | Health Services |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
VG Partners
VG Partners Investment ManagersFinance VG Partners is a private equity investment firm. The private company is based in Toronto, Canada. and has subsidiaries in Canada. | Finance |
Modulate Therapeutics, Inc.
Modulate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada. | Health Technology |
AurKa Pharma, Inc.
AurKa Pharma, Inc. BiotechnologyHealth Technology AurKa Pharma, Inc. develops medication for cancer treatment. The company was founded by Caroline Fortier and is headquartered in Montreal, Canada. | Health Technology |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
Panthera Dental Inc.
Panthera Dental Inc. Medical SpecialtiesHealth Technology Panthera Dental Inc. engages in prosthetic implant solutions and dental sleep appliances. Its products include metal implant bar, integrated bar, diamart, ReBourke, Copywax, Angulated Screw Channel, and Components and Attachment. The company was founded by Bernard Robichaud, Gabriel Robichaud, and Beatrice Robichaud in 2011 and is headquartered in Quebec, Canada. | Health Technology |
TVM Life Science Management, Inc. | Finance |
PRCL Research Inc.
PRCL Research Inc. Medical/Nursing ServicesHealth Services PRCL Research Inc. is a special purpose company created to develop one compound to proof-of-concept. It engages in the development of a clinical candidate against a novel target for the treatment of chronic inflammatory diseases. The company was founded on October 4, 2013 and is headquartered in Montreal, Canada. | Health Services |
- Borsa valori
- Insiders
- Luc Marengère